Neurohormonal abnormalities in heart failure: Impact of exercise training

Congestive Heart Failure

Volumn 9, Issue 2, 2003, Pages 70-76

  Braith, Randy W ^a   Edwards, David G ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF NEW HAMPSHIRE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALDOSTERONE; ANGIOTENSIN; ARGIPRESSIN; CATECHOLAMINE; CLONIDINE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAZOLINE RECEPTOR; MOXONIDINE; NATRIURETIC FACTOR; NEUROHORMONE; NORADRENALIN; PHENYLEPHRINE;

ARTERIAL PRESSURE; AUTONOMIC NERVOUS SYSTEM; BORDERLINE HYPERTENSION; CATECHOLAMINE BLOOD LEVEL; CAUSE OF DEATH; CHOLINERGIC ACTIVITY; CHOLINERGIC SYSTEM; CHRONOTROPISM; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG MEGADOSE; DRUG SELECTIVITY; DRUG TOXICITY; ENDURANCE; EXERCISE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART RATE; HEART RATE VARIABILITY; HORMONE ACTION; HORMONE DETERMINATION; HORMONE RESPONSE; HUMAN; KINESIOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; OXYGEN CONSUMPTION; PRESSORECEPTOR; PRESSORECEPTOR REFLEX; PROTEIN FUNCTION; RECEPTOR SENSITIVITY; REFLEX ARC; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RR INTERVAL; SIDE EFFECT; SURVIVAL RATE; SUSTAINED RELEASE PREPARATION; SYMPATHETIC TONE; VASCULAR RESISTANCE; WALKING;

EID: 0037363670     PISSN: 10797998     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-5299.2003.00277.x     Document Type: Review

References (55)

1. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-923.
2. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248-254.
3. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82:1730-1736.
4. Tan LB, Jalil JE, Pick R, et al. Cardiac myocyte necrosis induced by angiotensin II. Circ Res. 1991;69:1185-1195.
5. Grassi G, Cattaneo BM, Seravalle G, et al. Effects of chronic angiotensin-converting enzyme inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation. 1997;96:1173-1179.
6. Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation. 1997;96: 4065-4082.
7. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
8. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
9. Belardinelli R, Georgiou D, Cianci G, et al. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation. 1999;99:1173-1182.
10. Cooksey JD, Reilly P, Brown S, et al. Exercise training and plasma catecholamines in patients with ischemic heart disease. Am J Cardiol. 1978;42:372-376.
11. Williamson JW, Raven PB. Unilateral carotid-cardiac baroreflex responses in exercise trained and untrained men. Med Sci Sports Exerc. 1994;26:217-223.
12. Geyssant A, Geelen G, Denis C, et al. Plasma vasopressin, renin activity, and aldosterone: effect of exercise and training. Eur J Appl Physiol. 1981;46:21-30.
13. Convertino VA, Adams WC. Enhanced vagal baroreflex response during 24 hours after acute exercise. Am J Physiol. 1991;260:R570-R575.
14. Engelke KA, Shea JD, Doerr DF, et al. Autonomic functions and orthostatic responses 24 hours after acute intense exercise in paraplegic subjects. Am J Physiol. 1994;266:R1189-R1196.
15. Pagani M, Somers V, Furlan R, et al. Changes in autonomic regulation induced by physical training in mild hypertension. Hypertension. 1988;12:600-610.
16. Colucci WS. The sympathetic nervous system in heart failure. In: Hosenpud JD, Greenberg BH, eds. Congestive Heart Failure. Philadelphia, PA: Lippincott, Williams & Wilkins; 2000:189-197.
17. Ferrario CM, Gildenberg PL, McCubbin JW. Cardiovascular effects of angiotensin mediated by the central nervous system. Circ Res. 1972;30:257-262.
18. Lewis GP, Reit E. The action of angiotensin and bradykinin on the superior cervical ganglion of the cat. J Physiol (Lond). 1965; 179:538-553.
19. Zimmerman BG. Actions of angiotensin on adrenergic nerve endings. Fed Proc. 1978;37:199-202.
20. Hirsch AT, Dzau VJ, Creager MA. Baroreceptor function in congestive heart failure: effect on neurohumoral activation and regional vascular resistance. Circulation. 1987;75:IV36-IV48.
21. Wang W, Chen JS, Zucker IH. Carotid sinus baroreceptor sensitivity in experimental heart failure. Circulation. 1990;81: 1959-1966.
22. Olivari MT, Levine TB, Cohn JN. Abnormal neurohumoral response to nitroprusside infusion in congestive heart failure. J Am Coll Cardiol. 1983;23:411-417.
23. Levine TB, Francis GS, Goldsmith SR, et al. The neurohumoral and hemodynamic response to orthostatic tilt in patients with congestive heart failure. Circulation. 1983;67:1070-1075.
24. Ellenbogen KA, Mohanty PK, Szentpetery S, et al. Arterial baroreflex abnormalities in heart failure: reversal after orthotopic cardiac transplantation. Circulation. 1989;79:51-58.
25. Ferguson DW, Abboud FM, Mark AL. Selective impairment of baroreflex-mediated vasoconstrictor responses in patients with ventricular dysfunction. Circulation. 1984;69:451-460.
26. Kober L, Torp-Pedersen C, Carlsen JE, et al. Clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333:1670-1676.
27. Braith RW, Welsch MA, Feigenbaum MS, et al. Neuroendocrine activation in heart failure is modified by endurance exercise training. J Am Coll Cardiol. 1999;34:1170-1175.
28. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
29. Packer M. Effects of β-blockers on symptoms and survival of patients with chronic heart failure. Am J Cardiol. 1997;80: 46L-54L.
30. Clark WA, Rudnick SJ, LaPres JJ, et al. Regulation of hypertrophy and atrophy in cultured adult heart cells. Circ Res. 1993; 73:1163-1176.
31. Communal C, Singh K, Pimentel DR, et al. NE stimulates apoptosis in adult rat ventricular myocytes by activation of the β-adrenergic pathway. Circulation. 1998;98:1329-1334.
32. Coats AJ, Adamopoulos S, Radaelli A, et al. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function. Circulation. 1992;85:2119-2131.
33. Hambrecht R, Niebauer J, Fiehn E, et al. Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles. J Am Coll Cardiol. 1995;25:1239-1249.
34. Kiilavuori K, Naveri H, Leinonen H, et al. The effect of physical training on hormonal status and exertional hormonal response in patients with chronic congestive heart failure. Eur Heart J. 1999;20:456-464.
35. Belardinelli R, Georgiou D, Scocco V, et al. Low intensity exercise training in patients with chronic heart failure. J Am Coll Cardiol. 1995;26:975-982.
36. Keteyian SJ, Brawner CA, Schairer JR, et al. Effects of exercise training on chronotropic incompetence in patients with heart failure. Am Heart J. 1999;138:233-240.
37. Manolis AJ, Olympios C, Sifaki M, et al. Chronic sympathetic suppression in the treatment of chronic congestive heart failure. Clin Exp Hypertens 1998;20:717-731.
38. Girgis I, Chakko S, de Marchena E, et al. Effect of clonidine on heart rate variability in congestive heart failure. Am J Cardiol. 1998;82:335-337.
39. Dickstein K, Manhenke C, Aarsland T, et al. Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1999;83:1638-1644.
40. Swedberg K, Bergh CH, Dickstein K, et al., for the Moxonidine Investigators. The effects of moxonidine, a novel imidazoline, on plasma NE in patients with congestive heart failure. J Am Coll Cardiol. 2000;35:398-404.
41. Coats AJS. Editorial: heart failure 1999: the Moxcon story. Int J Cardiol. 1999;71:109-111.
42. Brouwer J, van Veldhuisen DJ, Man in't Veld AJ, et al. Prognostic value of heart rate variability during long-term follow-up in patients with mild to moderate heart failure. The Dutch Ibopamine Multicenter Trial Study Group. J Am Coll Cardiol. 1996;28:1183-1189.
43. Casolo GC, Stroder P, Sulla A, et al. Heart rate variability and functional severity of congestive heart failure secondary to coronary artery disease. Eur Heart J. 1995; 16:360-367.
44. Szabo BM, van Veldhuisen DJ, van der Veer N, et al. Prognostic value of heart rate variability in chronic congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol. 1997;79:978-980.
45. Ponikowski P, Anker SD, Chua TP, et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1997;79:1645-1650.
46. Bonaduce D, Petretta M, Marciano F, et al. Independent and incremental prognostic value of heart rate variability in patients with chronic heart failure. Am Heart J. 1999;138:273-284.
47. Townend JN, West JN, Davies MK, et al. Effect of quinapril on blood pressure and heart rate in congestive heart failure. Am J Cardiol. 1992;69:1587-1590.
48. Kiilavuori K, Toivonen L, Naveri H, et al. Reversal of autonomic derangements by physical training in chronic heart failure assessed by heart rate variability. Eur Heart J. 1995;16: 490-495.
49. Radaelli A, Coats AJ, Leuzzi S, et al. Physical training enhances sympathetic and parasympathetic control of heart rate and peripheral vessels in chronic heart failure. Clin Sci (Colch). 1996;91: 92-94.
50. Adamopoulos S, Ponikowski P, Cerquetani E, et al. Circadian pattern of heart rate variability in chronic heart failure patients. Effects of physical training. Eur Heart J. 1995;16:1380-1386.
51. Baker KM, Aceto JF. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol. 1990;259: H610-H618.
52. Schorb W, Booz GW, Dostal DE, et al. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ Res. 1993;72: 1245-1254.
53. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res. 1993;73:413-423.
54. Packer M. Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. Eur Heart J. 1990;11(suppl)D:44-52.
55. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203-210.